What the studies show
Female CBA mice given vilon from six months lived longer and developed fewer spontaneous tumours in the institute's studies; the same group reports opposite-direction effects in other models.
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
- 1Khavinson VK, et al. Effect of vilon on biological age and lifespan in mice.Bull Exp Biol Med, 2000Mice.
In context
Vilon is the dipeptide lysine–glutamate, one of the short synthetic peptides derived by Vladimir Khavinson's St Petersburg institute from thymic extracts and sold as an immune and anti-ageing 'bioregulator'. Its indexed evidence is mice — longer lifespan and fewer spontaneous tumours in the institute's own studies — and cultured cells. No human trial of any design exists. It is not approved anywhere this site covers.
Vilon is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Vilon proven to help with lifespan and tumour incidence?
What studies are behind the grade?
Is Vilon approved for this?
Other outcomes for Vilon
Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →